PET/CT imaging to track CD8+ T-cells in COVID-19 patients.
- Conditions
- Proven COVID-19.Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Registration Number
- EUCTR2020-005984-29-NL
- Lead Sponsor
- Radboud University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 20
All patients must meet all of the following criteria:
1. microbiologically proven SARS-CoV-19 infection;
2. More than or equal to 18 years of age;
3. Ability to provide written informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10
A patient will be excluded from participation in the trial if one or more of the following criteria are met:
1. Contra-indication for PET; pregnancy, breast-feeding, severe claustrophobia
2. Contra-indication for administration of iodine-containing contrast agents
3. Other serious illness, e.g. history of malignancies or auto-immune disorders
4. Known pre-existing lymphopenia from an unrelated other medical condition
5. Estimated creatinine clearance = 30mL/min according to the Cockcroft-Gault formula (or local institutional standard method) OR oligo-uric patients (<400mL/24hr)
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method